Retrotope is currently assessing technical proof of principle, regulatory requirements, and viability of several products in multiple market segments.
The company has a pipeline of products, including single agent and multiple stabilized polyunsaturated fatty acids (PUFAs), stabilized amino acids, each in a variety of indications.
Pharmaceutical candidates include:
a. Fortified lysine: Anti-metastatic agent against cancer proliferation and fibrotic disease, downregulating the effects of LOX, a well documented target for pathological collagen crosslinking.
b. Stabilized fatty acids: Treatment and high risk mitigation of diseases involving oxidative mitochondrial membrane damage. Anti-proliferative for protein damage and aggregation in Parkinson's and other orphan CNS diseases, using stabilized fatty acid mimetics.
c. Episodic or regular intervention for radiation exposure events or at high radiation- risk populations (e.g. security personnel, military, etc).
Health and Wellness
a. Cosmetics and skin care additives (licensing)
b. Pet product functional foods against cancer /enhancing lifetime in pets.
Other antioxidative applications of isotopic fortification of bonds are available for licensing discussions. These include: